ACTG Highlights

Established and continuing to manage the Treatment IND for trimetrexate for
patients intolerant to standard therapies.
Established and continue to manage an open protocol for trimetrexate for patients
refractory to standard therapies.
In less than 1 year, completed accrual for a 600-patient primary PCP prophylaxis
study of AP vs. dapsone vs. TMP/S.
CMV Retinitis
Developed an intermittent dosing schedule for foscarnet, previously administered
only by continuous IV infusion.
Established the appropriate range of maintenance doses of foscarnet for use in
further trials.
Established ganciclovir Treatment IND for patients with newly-diagnosed CMV
retinitis, yielding supporting evidence for the ganciclovir NDA.
Produced preliminary evidence that GM-CSF may be useful in limiting the
number of episodes of ganciclovir-induced neutropenia.
Initiated a dose-ranging study of FIAC in patients who shed CMV in order to
examine its antiviral effect, pharmacokinetics and tolerance.
Histoplasmosis
Demonstrated the feasibility of using itraconazole for suppression of relapse of
disseminated histoplasmosis in AIDS patients.
Cryptococcal Meningitis
Contributed pivotal data to support the licensing of fluconazole for acute
treatment.
Demonstrated that fluconazole is better tolerated and at least as effective as the
standard therapy, amphotericin B, for maintenance treatment of cryptococcal
meningitis.
Oncology
Demonstrated that low dose multidrug chemotherapy (mBACOD) is as effective as, and
less toxic than, a high dose regimen in patients with non-Hodgkins lymphoma.
Defined safety, maximnal tolerated dose, and drug interactions of AZT and alpha
interferon for Kaposi's sarcoma (KS) therapy, ensuring safe concomitant administration
of the two compounds.